service maintenance of the centrifuge Equipment

Solicitation #
HHSN-NIH-CCOPC-SBSS-19-002224

This is a Small business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources:(2) whether there are small businesses, HUBZONE small businesses, service disabled veteran-owned small businesses or (8a) small businesses, veteran- owned small business, woman-owned small businesses or small disadvantaged businesses veteran owned small businesses; woman owned businesses, or small disadvantaged businesses and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your response to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable code should not submit a response to this notice.

Background Information
The National Institutes of Health (NIH) is the nation's foremost federally funded biomedical research institution. It is comprised of twenty-seven Institutes and Centers. The NIH Clinical Center (CC) is the onsite hospital for the NIH campus, providing full support for clinical studies in inpatient and outpatient settings. The NIH CC is an 870,000 square-foot facility with the capacity to serve 240 inpatient beds and 82 day-hospital stations.

The Cell Processing Section (CPS), Department of Transfusion Medicine, NIH CC is an AABB accredited cellular therapy laboratory whose central mission is to provide services to the NIH Institutes to support more than 50 intramural clinical trials. These services include (1) development, evaluation, and validation of investigational new drugs (INDs) for cellular therapies and (2) manufacture of cellular therapy products for approved clinical trials. The majority of these trials are early phase (I/II) trials not intended to result in the development of a commercial product. To provide these services, CPS operates a core facility (Charles S. Carter Cellular Therapy Laboratory) for the manufacture, storage, and distribution of cellular therapy products. CPS manufactures cellular therapy products from more than 800 collections from patients or healthy donors per year. The products manufactured by the laboratory are used to treat NIH CC patients with cancer, hematological malignancies, marrow failure, genetic immune disorders and autoimmune diseases. All products are manufactured using good manufacturing practices (GMP). The NIH protocols are institutional review board (IRB) approved and in the case of INDs approval by the US Food and Drug Administration (FDA) for treatment of human subjects. Each subject must consent to participate in a NIH Clinical Research Study.

I. Objective

This contract is to provide Instrument service agreement for top centrifuge and cell washers.

II. Scope of Work

Preventive maintenance only, as unit is already covered under manufacturer's warranty. Twice yearly
RPM check, plus once yearly check for expected functioning per manufacturer's specifications.

III. SCHEDULE CARE
The Schedule Care Plan provides thorough annual preventive onsite by certified service engineers. The specialist will inspect, clean, check, adjust and run all appropriate tests to ensure that the lab equipment continues to meet the manufacturer's performance standards. While this plan does not cover the cost of repairs, it will assure priority service.
Key features include:
* Annual onsite preventive maintenance (labor and travel included)
* Priority scheduling for time and material onsite repair
* Priority scheduling for time and material depot repairs
* Phone and e-mail support

IV. TOTAL CARE
The Total Care Plan is the contractor's most comprehensive support plan for lab equipment. It minimizes downtime through responsive onsite service through annual preventive maintenance by factory-certified service engineers, plus optimal performance for equipment with the inclusion of the cost of repair.
Key features include:
* Priority onsite repair
* Annual onsite preventive maintenance
* All labor, parts and travel time covered 100%
* Priority depot repair
* Unlimited priority phone and e-mail support

This acquisition will be processed in accordance with Simplified acquisition procedures as stated in FAR 12 and under FAR 6.302 -1

V. Period of Performance

The period of performance is 12 months with an option of up to four (4) one year option periods.

Location:
NIH/CC/DTM/Cell Processing Section
10 Center Drive
Bldg. 10/ Rm. 3C720
Bethesda, MD 20892-1288
Attention: Timmy Ton

The contractor shall support service maintenance of centrifuge. The equipment is used in the manufacture of blood components, and of Transfusion Medicine of patients at the Clinical Center.

Capability Statement is to include:

Information regarding respondents; (a)
, including their availability, experience and informal and other training; (b) current in-house capability to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts; references, and other related information:

• Respondents, DUNS number, organization name, address, point of contract, and size and type of business (e.g.8(a), HUBZone, etc) pursuant to the applicable NAICS code;

• Respondents; technical and administrative points of contract including names, titles addresses, telephone and fax numbers and email addresses;

• Respondents must respond to this notice by December 12, 2018 at 12:00 pm Est

DISCLAIMER AND IMPORTANT NOTICES:
This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After review of the responses received, a pre-solicitation synopsis and solicitation maybe published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a future solicitation.

Primary Point of Contact

Priscilla Abalos Contract Specialist
Phone Number 301/594/5918

.